BC 028 – Efficacité de la dapagliflozine chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée (étude DAPA-HF)

BaladoCritique - club de lecture médical

Contenu fourni par Dr Luc Lanthier et collaborateurs and Dr Luc Lanthier. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Dr Luc Lanthier et collaborateurs and Dr Luc Lanthier ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

4+ y ago 48:37

MP3•Maison d'episode

Série archivée ("Flux inactif" status)

When? This feed was archived on August 20, 2023 01:52 (8M ago). Last successful fetch was on June 27, 2023 03:37 (10M ago)

Why? Flux inactif status. Nos serveurs ont été incapables de récupérer un flux de podcast valide pour une période prolongée.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dans cette 28e baladodiffusion, les Drs Luc Lanthier et Charles Dussault discutent de l’efficacité de la dapagliflozine (Forxiga®), un inhibiteur des SGLT2, chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée avec l’étude DAPA-HF, en plus de réviser la littérature médicale de septembre 2019.

Quiz clinique (3min15), étude principale (3min45), critique (21min40), autres articles (32min27), réponse au quiz clinique (45min00)

Référence principale

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019. doi: 10.1056/NEJMoa1911303. PubMed PMID: 31535829.

Articles associés

https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51. PubMed PMID: 31185157.

Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019. doi: 10.1161/CIRCULATIONAHA.119.042929. PubMed PMID: 31524498.

Fang JC. Heart-Failure Therapy – New Drugs but Old Habits? N Engl J Med. 2019. doi: 10.1056/NEJMe1912180. PubMed PMID: 31535828.

Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019. doi: 10.1056/NEJMoa1908973. PubMed PMID: 31475799.

Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. PubMed PMID: 31492505.

Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019. doi: 10.1056/NEJMoa1908419. PubMed PMID: 31556978.

Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019. doi: 10.1056/NEJMoa1909406. PubMed PMID: 31562798.

Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-66. PubMed PMID: 30025570.

Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(19):2365-83. PubMed PMID: 30844480.

Autres articles d’intérêt

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. PubMed PMID: 31475793.

Mrkobrada M, Chan MTV, Cowan D, Campbell D, Wang CY, Torres D, et al. Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. Lancet. 2019;394(10203):1022-9. PubMed PMID: 31422895.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919-28. PubMed PMID: 31451207.

Guides de pratique

GINA asthme : https://ginasthma.org/gina-reports/

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12. PubMed PMID: 31385462.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, et al. Canadian guideline for Parkinson disease. CMAJ. 2019;191(36):E989-E1004. PubMed PMID: 31501181.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-e95PubMed PMID: 30879339.

Référence du quiz clinique

https://www.cancer.ca/fr-ca/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=qc

50 episodes

#Éducation #Dr Luc Lanthier et collaborateurs #Dr Luc Lanthier